Lisa R. Tannock, MD

Chief, Division of Endocrinology and Molecular Medicine

Clinical interests

  • Diabetes
  • General Endocrinology
  • Lipids
  • Metabolic Disease

Lisa R. Tannock, MD

Chief, Division of Endocrinology and Molecular Medicine


My name is Lisa Tannock; I received my medical degree from the University of Toronto, Ontario, Canada. I then completed a fellowship at the University of Washington Medical Center, Seattle. I joined the University of Kentucky in 2004, and became division chief in 2007, and associate chair of internal medicine for administration in 2014.

I am board certified by the American Board of Internal Medicine in Endocrinology and Metabolism. I have been the associate editor of the peer-reviewed journal, Atherosclerosis, since 2008. I am associate director of the Barnstable Brown Diabetes and Obesity Center and an incoming editor in chief for the Endocrine Self Assessment Program.

My research interests include studying how diabetes and obesity complications develop. My clinical interests include diabetes and insulin resistance, cholesterol disorders and transgender medicine.

Faculty rank

Professor of Medicine


University of Toronto, Ontario, Canada

University of Toronto Hospitals, Ontario, Canada

University of Washington Medical Center, Seattle

Certifications or Special training
American Board of Internal Medicine, Endocrinology and Metabolism 


Medicine Specialties

Kentucky Clinic
Second Floor, Wing C
740 S. Limestone
Lexington KY 40536-0284

Call 859-323-2232
Fax 859-257-2634

Dining, Internet/Wi-Fi, Information desk, Pharmacy services, Wheelchairs

Kentucky Clinic Map (PDF, 616 KB) »
Directions to Kentucky Clinic Parking »

UK HealthCare accepts many forms of insurance. See list of insurers »


Recent Publications

(Five most recent publications from PubMed via an automated list based on the provider’s ID and the University of Kentucky.)
  1. Grandoch M, Kohlmorgen C, Melchior-Becker A, Feldmann K, Homann S, Müller J, Kiene LS, Zeng-Brouwers J, Schmitz F, Nagy N, Polzin A, Gowert NS, Elvers M, Skroblin P, Yin X, Mayr M, Schaefer L, Tannock LR, Fischer JW.
    Loss of Biglycan Enhances Thrombin Generation in Apolipoprotein E-Deficient Mice: Implications for Inflammation and Atherosclerosis.
    Arterioscler Thromb Vasc Biol. 2016 May;36(5):e41-50.
  2. Palladino CE, Eberly ME, Emmons JT, Tannock LR.
    Management of U-500 insulin users during inpatient admissions within a Veterans Affairs Medical Center.
    Diabetes Res Clin Pract. 2016 Apr;114:32-6.
  3. Thompson JC, Jayne C, Thompson J, Wilson PG, Yoder MH, Webb N, Tannock LR.
    A brief elevation of serum amyloid A is sufficient to increase atherosclerosis.
    J Lipid Res. 2015 Feb;56(2):286-93.
  4. Tannock LR.
    Vascular proteoglycans and atherosclerosis: not over yet.
    Atherosclerosis. 2014 Dec;237(2):435-6.
  5. Tang T, Thompson JC, Wilson PG, Yoder MH, Müeller J, Fischer JW, Williams KJ, Tannock LR.
    Biglycan deficiency: increased aortic aneurysm formation and lack of atheroprotection.
    J Mol Cell Cardiol. 2014 Oct;75:174-80.

View this provider on PubMed